conflict of interest statement anthony defranco identified conflicts of interest -i am on the...

34
Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB- Pharma, a pharmaceutical company that sells anti- inflammatory drugs (one of the five approved TNF blockers) and anti-histamines. Additional immunology-related therapeutics are in late phase clinical testing -My wife and I own stock in several biotechnology companies that make anti-inflammatory drugs and/or are currently in late phases of testing such drugs Management of conflicts of interest -I will not comment on relative advantages or disadvantages of specific products or potential products made by these companies vs. competitive products of other companies

Upload: essence-edgett

Post on 15-Dec-2015

217 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Conflict of Interest StatementAnthony DeFranco

Identified conflicts of interest-I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical company that sells anti-inflammatory drugs (one of the five approved TNF blockers) and anti-histamines. Additional immunology-related therapeutics are in late phase clinical testing-My wife and I own stock in several biotechnology companies that make anti-inflammatory drugs and/or are currently in late phases of testing such drugs

Management of conflicts of interest-I will not comment on relative advantages or disadvantages of specific products or potential products made by these companies vs. competitive products of other companies

Page 2: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Inflammation and Innate Immunity (part I)

• Inflammation• Innate immunity and the initial response to

infection• Cytokines that induce inflammation and

direct inflammatory cells• Recognition of microbes by Toll-like

receptors (TLRs) and other innate recognition elements

• Inflammation and recruitment of phagocytes• Uptake and killing of bacteria by phagocytes• Innate immunity against fungi, helminths, at

mucosal epithelium

Page 3: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Source: Wikipedia

QuickTime™ and a decompressor

are needed to see this picture.

Inflammation

Page 4: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Inflammation

“rubor et tumor cum calore et dolore”

(redness and swelling with heat and pain)

--Cornelius Celsus in De Medicina, 1st century A.D.

later “functio laesa” (disturbance of function) was added

Page 5: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Inflammation

“rubor et tumor cum calore et dolore”

(redness and swelling with heat and pain)

--Cornelius Celsus in De Medicina, 1st century A.D.

later “functio laesa” (disturbance of function) was added

Inflammation is an adaptive response to noxious conditions (infection and tissue injury)--an attempt to restore homeostasis

Page 6: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Inflammation

• Inflammation can be induced by immune recognition of infection or tissue damage (usually good)

• Inflammation can be induced by immune recognition that is hypersensitive to environmental components or autoinflammatory or autoimmune (=disease)

Page 7: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Inflammation

• Inflammation can be induced by immune recognition of infection or tissue damage (usually good)

• Inflammation can be induced by immune recognition that is hypersensitive to environmental components or autoinflammatory or autoimmune (=disease)

• Acute inflammation: influx of white blood cells and fluid from blood to fight infection and aid tissue repair

• Chronic inflammation: inducer of inflammation is not removed– Leads to tissue damage and loss of tissue function (joint

destruction, lung fibrosis, etc.)– Current view: aggressively fight inflammation in certain

chronic diseases to decrease/delay progressive loss of function

Page 8: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Inflammation

• Inflammation can be induced by immune recognition of infection or tissue damage (usually good)

• Inflammation can be induced by immune recognition that is hypersensitive to environmental components or autoinflammatory or autoimmune (=disease)

• Acute inflammation: influx of white blood cells and fluid from blood to fight infection and aid tissue repair

• Chronic inflammation: inducer of inflammation is not removed– Leads to tissue damage and loss of tissue function (joint

destruction, lung fibrosis, etc.)– Current view: aggressively fight inflammation in certain chronic

diseases to decrease/delay progressive loss of function• Current research suggests that inflammation may play an important

role in common chronic diseases including atherosclerosis, type 2 diabetes, neurodegeneration, and cancer

Page 9: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Immune sentinel cells in the tissues: dendritic cells

Langerhans cells (epidermal dendritic cells) in the skinWJ Mullholland et al. J. Invest. Dermatol. 126: 1541, 2006.

QuickTime™ and a decompressor

are needed to see this picture.

Green= dendritic cellsBlue= nuclei of all cells

Page 10: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Infection leads to production of inducers of inflammation

TNF

or dendritic cell

Inflammatory mediators:Complex and many, but include:Lipids andProteins (cytokines/chemokines)

Others

QuickTime™ and a decompressor

are needed to see this picture.

Page 11: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Cytokines• “Cytokines” are soluble protein mediators secreted by

immune cells (mostly) that act on other cells to regulate their activity; many are called “interleukins” (IL-1, IL-2, etc.) (note: sometimes exist in cell-bound forms)

• Cytokines have many functions, we’ll focus on a few central functions of some key cytokines (see “Cytokine primer” in syllabus)

• Name of a cytokine often doesn’t reflect its most important function (example: TNF stands for “tumor necrosis factor” but main function is to induce inflammation)

• A subfamily of cytokines primarily functions in directing migration of cells, these are called “chemotactic cytokines” or “chemokines”

Chemokines have systematic names: CCL1, 2, … and CXCL1, 2, …(but older names sometimes used, including IL-8)

Page 12: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

The Initial Response to Infection: Innate Immunity

• Recognition of types of molecules (“molecular patterns”) made by microbes or viruses but not by our cells by innate immune receptors

• Alternatively, recognition of tissue damage and cell death, which are often associated with infection (“danger”).

• Rapid mobilization of leukocytes to the site of infection or damage and influx of plasma into the tissue site (=inflammation)

• Recruited innate immune cells kill microbes or virally infected cells. Immune cells also can promote tissue repair but when dysregulated can exacerbate tissue injury

• Also, innate recognition promotes the adaptive immune response, which is slower but more powerful

Page 13: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Cytokines and Inflammation

• Macrophages or DCs stimulated via innate immune receptors make pro-inflammatory cytokines, especially TNF (Tumor necrosis factor), IL-1, and IL-6

• TNF and IL-1 signal to endothelial cells to make them:– Leaky to fluid (influx of plasma; containing

antibodies, complement components, etc.)– Sticky for leukocytes, leading to influx of first

neutrophils, later monocytes, lymphocytes• IL-6 promotes adaptive immune responses and has

systemic effects (“acute phase response” of liver, including C-reactive protein or CRP; levels used clinically as an indication of systemic inflammation)

Page 14: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Leukocyte recruitment to sites of inflammation

See Abbas and Lichtman Fig. 2-7

or DCQuickTime™ and a

decompressorare needed to see this picture.

Note: molecular details of leukocyte extravasation will be covered in lecture Thursday

Page 15: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Inflammation: Neutrophils vs. Monocytes

• Acute inflammation is initially characterized as rich in neutrophils; later it is more monocytes and lymphocytes. This is controlled by which chemokines are expressed by the endothelial cells.

• Neutrophils are dedicated to killing microbes and are short-lived. They often damage host tissue as a byproduct.

• Monocytes are multi-potential, depending on cytokine signals:

+IFN-g: assume a vigorous killing phenotype similar to neutrophils

+IL-4: “alternatively activated macrophages”; tissue repair, barrier immunity

+IL-10: assume a wound-healing type phenotype (to clean up after infection is cleared)

Page 16: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Anti-Inflammatory Therapeutics

• NSAIDs: inhibitors of inflammation and fever (block prostaglandin synthesis)

• Glucocorticoids are also potent anti-inflammatory drugs; natural systemic anti-inflammatory mechanism

• Agents that block TNF are effective in treating rheumatoid arthritis, Crohn’s disease, etc.

• Agents that block IL-1 are less effective for these diseases but are useful for some genetic inflammatory diseases

Page 17: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

How is infection first recognized by the immune system?

• What is seen by innate immunity?– Types of molecules made by microbes, but not by our cells

“Pathogen-associated molecular patterns” PAMPs– Molecules released from necrotic cells, tissue damage

(“damage-associated molecular patterns” DAMPs). (Note: tissue damage can also be recognized by pain neurons, which can promote inflammation)

• What mediates the recognition?– Diverse recognition elements; 4 key families of cellular

receptors:• Toll-like receptors (TLRs)• C-type lectin receptors (CLRs)• RigI-like receptors (RLRs)• NOD-like receptors (NLRs)

Page 18: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Innate recognition outside the cell or in endosomes:TLRs and CLRs

Modified from Abbas and Lichtman Fig. 2-2

CLRs detect mostly carbohydrates (fungi especially); also recognize dead host cells; induce cytokines

TLRs induce inflammatory cytokines (+ interferon)

Endosomal TLRs recognize nucleic acids (mostly from virus particles). Localization in endosomes is thought to aid discrimination between virus-derived and endogenous nucleic acids

Surface CLRscarbohydrates

TLR4 recognizes LPS

Page 19: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Sepsis Syndrome: very bad(too much of a good thing)

• Bacterial septicemia leads to activation of TLRs on monocytes in the blood, DCs in spleen

• Systemic release of TNF and IL-1 leads to “inflammation” all over the body

• Shock from loss of blood pressure (vasodilation and leakage of fluid into tissues)

• TLRs also induce coagulation (via tissue factor)– Current therapy with some efficacy: “activated protein

C”: promotes fibrinolysis, breaks down thrombi• The combination of effects frequently leads to

multi-organ failure and death

Page 20: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Innate recognition in the cytoplasm:NLRs and RLRs

Modified from Abbas and Lichtman Fig. 2-2

Inflammatory cytokines

Engulfment of bacteria invading the cytoplasm (autophagy)

Secrete anti-microbial peptides into lumen of crypts of sm. intest.

(RLRs)

Peptidoglycan

Page 21: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Common alleles of NOD2 are a genetic risk factor for Crohn’s

disease

• Several moderately common alleles of the NOD2 gene (7% of total alleles) increase susceptibility to Crohn’s disease (a form of inflammatory bowel disease)

• Two copies of these alleles increase susceptibility by 40X

• Mechanism: most evidence indicates these are loss-of-function alleles; unknown which function of NOD2 is most relevant

Page 22: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Processing of IL-1 and related cytokines: an important regulatory

step• Some “NLRs” assemble to form the “inflammasome” which

proteolytically processes IL-1 and related cytokines (IL-18) to their active, secreted forms.

• Inflammasome in activated by cellular stress or recognition of microbial components in the cytoplasm

Page 23: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Processing of IL-1 and related cytokines: an important regulatory

step• Some “NLRs” assemble to form the “inflammasome” which

proteolytically processes IL-1 and related cytokines (IL-18) to their active, secreted forms.

• Inflammasome in activated by cellular stress or recognition of microbial components in the cytoplasm

• Genetic periodic fever syndromes are due to activating mutations in the inflammasome (active when it shouldn’t be)

• Inflammasome is activated by some types of small crystals that can be phagocytosed by macrophages, important role in Gout

Page 24: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

The Inflammasome activates caspase 1 in response to cellular

insults

QuickTime™ and a decompressor

are needed to see this picture.

Phagocytosed crystalsBacterial pore-forming toxinsEfflux of K+

Bacterial flagellinOther insults/stresses

Several different NLRs can form inflammasomes (shown is NLRP3/NALP3)

QuickTime™ and a decompressor

are needed to see this picture.

Page 25: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Inducers of Inflammation

• Microbe PAMPs recognized by TLRs, NOD1/2 or CLRs: DCs, macrophages makeTNF and IL-1

• Virus infections: infected cells, pDCs make IFN/ (type 1)• Tissue damage (cell necrosis etc.): “DAMPs” activate DCs,

macrophages via TLRs, CLRs, inflammasomes (other receptors?)

• Complement fragments (innate activators or IgM or IgG + antigen)

• Mast cell activation (IgE+allergen or innate mechanisms: release histamine, leukotrienes, cytokines): eosinophil-rich inflammation (“type 2 immunity”)

• Effector T cells responding to antigen (TNF + other cytokines; chemokines)

Page 26: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Negative Regulation of Inflammation

• Cells responding to innate stimuli stop making inflammatory mediators after short time period and convert to making anti-inflammatory lipids (resolvins, etc.) and anti-inflammatory cytokines (IL-10, TGF-)

• Killing the infectious agent and removal of the dead cells, debris, crystals, etc. will stop stimulation of incoming inflammatory cells

• Systemic elevation of inflammatory cytokines (esp. IL-1) in severe infections induce production of glucocorticoids, which are anti-inflammatory (also increased by stress)

• Regulatory T cells are also anti-inflammatory, both by blocking effector T cells and by inhibiting innate cells

Page 27: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Phagocytosis and Killing of Microbes

Abbas and Lichtman Fig. 2-9

Page 28: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Phagocytosis and Killing of Microbes

Abbas and Lichtman Fig. 2-9

Key Concepts related to phagocytosis:

1. Opsonization: soluble immune recognition elements tag a particle for phagocytosis (opsonins include: Mannose-binding lectin, C3b, IgG, etc.)

2. Interferon- from NK cell or Th1 cell promotes killing of internalized microbes by monocytes/macrophages

3. Killing mechanisms: ROI, NO, proteases, anti-microbial peptides

Page 29: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Phagocytosis and Killing of Microbes

Abbas and Lichtman Fig. 2-9

Genetic defects in phagocyte oxidase components: “chronic granulomatous disease”

Key Concepts related to phagocytosis:

1. Opsonization: soluble immune recognition elements tag a particle for phagocytosis (opsonins include: Mannose-binding lectin, C3b, IgG, etc.)

2. Interferon- from NK cell or Th1 cell promotes killing of internalized microbes by monocytes/macrophages

3. Killing mechanisms: ROI, NO, proteases, anti-microbial peptides

Page 30: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Innate Immunity against fungal pathogens

• CLRs are key innate recognition elements for fungi/yeast (TLRs can also play a role)

• Neutrophils are important for killing most fungal pathogens

• Some fungal pathogens can establish intracellular infections (like some bacterial pathogens): interferon- is important for defense; often also NO

Page 31: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Innate Immunity against helminths

• Often multicellular parasites induce a “type 2” inflammation characterized by influx of eosinophils and basophils instead of neutrophils and monocytes

• This type of inflammation is also seen in asthma and allergies, as will be discussed later in the course and can be propagated by Th2 adaptive immunity and/or IgE

• Innate recognition is not yet understood, may include foreign polysaccharides (chitin), proteases, tissue damage

• In some parasitic worm infections inside tissue, bacteria in the gut/feces of the worm stimulate TLRs and neutrophil-rich inflammation, which can cause pathology (African river blindness)

Page 32: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Innate Immunity and Mucosal Epithelium

• Microbes are tolerated outside mucosal epithelium when consistent with its function (colon; upper airways)

• Efforts to keep microbes out of some mucosal epithelial regions (small intestines and small airways)

• Mechanisms include: actions of some surfactant proteins in lungs (bind to foreign polysaccharides); secretion of anti-microbial peptides by Paneth cells in crypts of small intestines; secretion of mucus by goblet cells; T cells in epithelial tissue; IgA

• IL-13 is an important cytokine promoting mucus secretion

Page 33: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

Tomorrow: Innate Immunity to Viruses

Page 34: Conflict of Interest Statement Anthony DeFranco Identified conflicts of interest -I am on the Scientific Advisory Board of UCB-Pharma, a pharmaceutical

REMINDER:The 1PM session is a live patient

interview session, so be here promptly by 1:10 and no electronics or eating food

when patient is on stage

Patient Confidentiality must be maintained